Trillium Therapeutics to price convertible preferred share units

By Abigail W. Adams

Portland, Me., Feb. 21 – Trillium Therapeutics Inc. plans to price an offering of series II non-voting convertible first preferred share units concurrently with an offering of common share units, according to a company news release.

Cowen and Co., LLC is the bookrunner for the off-the-shelf offering in the United States and Canada.

The convertible first preferred share units will consist of one series II non-voting convertible first preferred share and one series II non-voting convertible first preferred share purchase warrant.

The convertible preferred share units are being offered to investors who would beneficially own more than 4.99% of the company’s common shares through participation in the common share unit offering.

The common share units will consist of one common share and one common share purchase warrant.

Proceeds will be used for the development of its cancer immunotherapeutic program SIRPáFc, for working capital and for general corporate purposes.

Trillium Therapeutics is a Toronto-based immuno-oncology company focused on the development of cancer treatments.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.